Issue 2 Anticoagulation Matters:
DVT Treatment Edition

Exciting Medical Research Breakthroughs and Latest Thinking on Disease Management and DVT Treatment

A/Prof. Hitos: Exciting Medical Research Breakthroughs in Australia


Prof Ward: What are we doing well in the treatment of DVT in Australia?


LMWH: low molecular weight heparin VTE = venous thromboembolism.


1 Clexane Australian Product Information, 13 July 2018.
2 Fareed J et al. Semin Thromb Hemost 2004;30:706–13.

Date of preparation: August 2019. SM_SAN980. SAANZ.ENO.19.01.0069c

*Clexane Safety Lock as an automatic safety lock system.

Further information is available on request from Sanofi.


PBS Information: CLEXANE®. General Benefit Antithrombotic agent. Refer to PBS schedule for full information.CLEXANE® with Automatic Safety Lock System. Refer to PBS schedule for full information. CLEXANE® FORTE. This product is not listed on the PBS.

Please review Product Information before prescribing Clexane. Full Product Information is available by calling 1800 818 806 or by clicking here.

sanofi-aventis australia pty ltd training as Sanofi, ABN 31 008 558 807, Talavera Corporate Centre, Building D, 12-24 Talavera Road, Macquarie Park, NSW 2113. ®Clexane is a registered trademark of sanofi-aventis.

Clexane Safety Lock Webinars


Your patients' information portal for all VTE matters

Password: support

Receive future issues of Anticoagulation Matters, curated specifically for you.


Access patient information and resources on VTE and Clexane®.